OMCL Quote, Financials, Valuation and Earnings

Cryo-Cell International has a net margin of -2.6% compared to Omnicell's net margin of 3.55%. Omnicell's return on equity of 1.73% beat Cryo-Cell International's return on equity of --.

Omnicell has a consensus price target of $39.83, signalling upside risk potential of 41.1%. On the other hand Cryo-Cell International has an analysts' consensus of $8.50 which suggests that it could grow by 75.98%. Given that Cryo-Cell International has higher upside potential than Omnicell, analysts believe Cryo-Cell International is more attractive than Omnicell.

Omnicell has a beta of 0.776, which suggesting that the stock is 22.397% less volatile than S&P 500. In comparison Cryo-Cell International has a beta of 0.724, suggesting its less volatile than the S&P 500 by 27.595%.

Omnicell has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International offers a yield of 13.46% to investors and pays a quarterly dividend of $0.15 per share. Omnicell pays -- of its earnings as a dividend. Cryo-Cell International pays out 502.5% of its earnings as a dividend.

Omnicell quarterly revenues are $269.7M, which are larger than Cryo-Cell International quarterly revenues of $8M. Omnicell's net income of -$7M is lower than Cryo-Cell International's net income of $282.9K. Notably, Omnicell's price-to-earnings ratio is 61.37x while Cryo-Cell International's PE ratio is 483.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omnicell is 1.16x versus 1.23x for Cryo-Cell International. Usually stocks with elevated PS ratios are considered overvalued.

Evolent Health has a net margin of -2.6% compared to Omnicell's net margin of -13.36%. Omnicell's return on equity of 1.73% beat Evolent Health's return on equity of -10.73%.

Omnicell has a consensus price target of $39.83, signalling upside risk potential of 41.1%. On the other hand Evolent Health has an analysts' consensus of $15.31 which suggests that it could grow by 112.31%. Given that Evolent Health has higher upside potential than Omnicell, analysts believe Evolent Health is more attractive than Omnicell.

Omnicell has a beta of 0.776, which suggesting that the stock is 22.397% less volatile than S&P 500. In comparison Evolent Health has a beta of 1.042, suggesting its more volatile than the S&P 500 by 4.162%.

Omnicell has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evolent Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Omnicell pays -- of its earnings as a dividend. Evolent Health pays out -32.59% of its earnings as a dividend.

Omnicell quarterly revenues are $269.7M, which are smaller than Evolent Health quarterly revenues of $483.6M. Omnicell's net income of -$7M is higher than Evolent Health's net income of -$64.6M. Notably, Omnicell's price-to-earnings ratio is 61.37x while Evolent Health's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omnicell is 1.16x versus 0.35x for Evolent Health. Usually stocks with elevated PS ratios are considered overvalued.

Phreesia has a net margin of -2.6% compared to Omnicell's net margin of -5.83%. Omnicell's return on equity of 1.73% beat Phreesia's return on equity of -22.95%.

Omnicell has a consensus price target of $39.83, signalling upside risk potential of 41.1%. On the other hand Phreesia has an analysts' consensus of $31.77 which suggests that it could grow by 32.04%. Given that Omnicell has higher upside potential than Phreesia, analysts believe Omnicell is more attractive than Phreesia.

Omnicell has a beta of 0.776, which suggesting that the stock is 22.397% less volatile than S&P 500. In comparison Phreesia has a beta of 0.738, suggesting its less volatile than the S&P 500 by 26.243%.

Omnicell has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phreesia offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Omnicell pays -- of its earnings as a dividend. Phreesia pays out -- of its earnings as a dividend.

Omnicell quarterly revenues are $269.7M, which are larger than Phreesia quarterly revenues of $109.7M. Omnicell's net income of -$7M is lower than Phreesia's net income of -$6.4M. Notably, Omnicell's price-to-earnings ratio is 61.37x while Phreesia's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omnicell is 1.16x versus 3.30x for Phreesia. Usually stocks with elevated PS ratios are considered overvalued.

Premier has a net margin of -2.6% compared to Omnicell's net margin of 10.36%. Omnicell's return on equity of 1.73% beat Premier's return on equity of 3.44%.

Omnicell has a consensus price target of $39.83, signalling upside risk potential of 41.1%. On the other hand Premier has an analysts' consensus of $22.00 which suggests that it could fall by -4.6%. Given that Omnicell has higher upside potential than Premier, analysts believe Omnicell is more attractive than Premier.

Omnicell has a beta of 0.776, which suggesting that the stock is 22.397% less volatile than S&P 500. In comparison Premier has a beta of 0.541, suggesting its less volatile than the S&P 500 by 45.858%.

Omnicell has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Premier offers a yield of 3.64% to investors and pays a quarterly dividend of $0.21 per share. Omnicell pays -- of its earnings as a dividend. Premier pays out 79.64% of its earnings as a dividend. Premier's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Omnicell quarterly revenues are $269.7M, which are larger than Premier quarterly revenues of $261.4M. Omnicell's net income of -$7M is lower than Premier's net income of $27.1M. Notably, Omnicell's price-to-earnings ratio is 61.37x while Premier's PE ratio is 42.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omnicell is 1.16x versus 1.78x for Premier. Usually stocks with elevated PS ratios are considered overvalued.